Carmela Ricciardelli

List of Publications by Year
in descending order

85	4,552	101384	106150
papers	citations	36 h-index	65 g-index

87	87	87	7196
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. Cancers, 2022, 14, 2362.	1.7	5
2	Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations. Cancers, 2022, 14, 2763.	1.7	4
3	Abstract 5184: Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors. Cancer Research, 2022, 82, 5184-5184.	0.4	1
4	ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. , 2021, 4, 485-502.		6
5	Targeting Aquaporins in Novel Therapies for Male and Female Breast and Reproductive Cancers. Cells, 2021, 10, 215.	1.8	13
6	Effect of Selenium and Iodine on Oxidative Stress in the First Trimester Human Placenta Explants. Nutrients, 2021, 13, 800.	1.7	9
7	The effect of zinc on human trophoblast proliferation and oxidative stress. Journal of Nutritional Biochemistry, 2021, 90, 108574.	1.9	2
8	Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics, 2021, 11, 69.	1.3	5
9	Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype. International Journal of Molecular Sciences, 2021, 22, 71.	1.8	12
10	Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug. International Journal of Molecular Sciences, 2021, 22, 10844.	1.8	3
11	A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. Cancers, 2021, 13, 4.	1.7	9
12	Ovarian cancerâ€associated mesothelial cells induce acquired platinumâ€resistance in peritoneal metastasis via the FN1/Akt signaling pathway. International Journal of Cancer, 2020, 146, 2268-2280.	2.3	41
13	A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecologic Oncology, 2020, 159, 827-838.	0.6	9
14	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 2020, 76, 976-987.	1.6	18
15	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. Journal of Clinical Medicine, 2020, 9, 2967.	1.0	23
16	Chick chorioallantoic membrane assay: a 3D animal model for cancer invasion and metastasis. , 2020, , 221-231.		2
17	Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 2019, 13, 2178-2193.	2.1	39
18	Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for Monitoring of Drug Response in Primary Cancer Spheroids. Proteomics, 2019, 19, 1900146.	1.3	13

#	Article	IF	Citations
19	4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer. Cancers, 2019, 11, 1187.	1.7	29
20	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Research, 2019, 39, 2475-2482.	0.5	9
21	Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 10.	3.5	26
22	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	2.3	13
23	ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients. Cellular Physiology and Biochemistry, 2019, 52, 1553-1568.	1.1	5
24	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 2018, 24, 2328-2341.	3.2	63
25	Novel exÂvivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics. Cancer Letters, 2018, 421, 51-58.	3.2	31
26	S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 4122.	1.8	32
27	Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance. Cancers, 2018, 10, 482.	1.7	54
28	Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. Oncogene, 2017, 36, 4469-4480.	2.6	32
29	Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. Oncotarget, 2017, 8, 17819-17832.	0.8	44
30	WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancerâ€“peritoneal cell interactions promote extracellular matrix processing. Endocrine-Related Cancer, 2016, 23, T155-T168.	1.6	21
31	WOMEN IN CANCER PROFILE: My pathway to understanding the role of the tumour microenvironment in cancer progression. Endocrine-Related Cancer, 2016, 23, P27-P31.	1.6	1
32	Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Translational Research, 2016, 171, 83-95.e2.	2.2	37
33	The role of ABC transporters in ovarian cancer progression and chemoresistance. Critical Reviews in Oncology/Hematology, 2015, 96, 220-256.	2.0	139
34	Hypoxia induced HIF-1/HIF-2 activity alters trophoblast transcriptional regulation and promotes invasion. European Journal of Cell Biology, 2015, 94, 589-602.	1.6	58
35	Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro-Oncology, 2015, 17, 200-210.	0.6	131
36	Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clinical and Experimental Metastasis, 2015, 32, 441-455.	1.7	50

#	Article	IF	Citations
37	Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk. Journal of Mammary Gland Biology and Neoplasia, 2015, 20, 121-131.	1.0	21
38	Overexpression of piRNA Pathway Genes in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e99687.	1.1	54
39	Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Letters, 2014, 342, 248-256.	3.2	78
40	Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 2013, 73, 182-193.	1.2	17
41	Androgen Receptor Protein Levels Are Significantly Reduced in Serous Ovarian Carcinomas Compared with Benign or Borderline Disease but Are Not altered by Cancer Stage or Metastatic Progression. Hormones and Cancer, 2013, 4, 154-164.	4.9	20
42	Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer, 2013, 13, 476.	1.1	66
43	The metalloproteinase ADAMTS1: A comprehensive review of its role in tumorigenic and metastatic pathways. International Journal of Cancer, 2013, 133, 2263-2276.	2.3	63
44	Small glutamine-rich tetratricopeptide repeatâ€“containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 2013, 99, 2076-2083.e1.	0.5	5
45	Conservation and Expression of PIWI-Interacting RNA Pathway Genes in Male and Female Adult Gonad of Amniotes1. Biology of Reproduction, 2013, 89, 136.	1.2	28
46	Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 7742-7756.	1.8	39
47	Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget, 2013, 4, 1199-1211.	0.8	58
48	Transforming Growth Factor-Beta-Induced Protein (TGFBI)/(Î²ig-H3): A Matrix Protein with Dual Functions in Ovarian Cancer. International Journal of Molecular Sciences, 2012, 13, 10461-10477.	1.8	96
49	Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis. International Journal of Molecular Sciences, 2012, 13, 9959-9970.	1.8	286
50	The ADAMTS1 Protease Gene Is Required for Mammary Tumor Growth and Metastasis. American Journal of Pathology, 2011, 179, 3075-3085.	1.9	64
51	Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery. International Journal of Molecular Sciences, 2011, 12, 410-428.	1.8	7
52	Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clinical and Experimental Metastasis, 2011, 28, 113-125.	1.7	58
53	The Role of Annexin A2 in Tumorigenesis and Cancer Progression. Cancer Microenvironment, 2011, 4, 199-208.	3.1	197
54	Transforming growth factorâ€betaâ€induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. International Journal of Cancer, 2011, 128, 1570-1584.	2.3	65

#	Article	IF	Citations
55	Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. International Journal of Molecular Sciences, 2011, 12, 1009-1029.	1.8	107
56	Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 2010, 23, 1045-52.	1.2	14
57	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	1.1	13
58	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2611-2622.	1.1	145
59	Androgen Receptor Inhibits Estrogen Receptor-Î± Activity and Is Prognostic in Breast Cancer. Cancer Research, 2009, 69, 6131-6140.	0.4	329
60	The biological role and regulation of versican levels in cancer. Cancer and Metastasis Reviews, 2009, 28, 233-245.	2.7	201
61	Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate, 2009, 69, 761-769.	1.2	16
62	Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas, 2009, 62, 270-275.	1.0	38
63	Elevated levels of HERâ€2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate, 2008, 68, 830-838.	1.2	43
64	Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2488-2497.	1.1	24
65	Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility. Journal of Biological Chemistry, 2007, 282, 10814-10825.	1.6	126
66	Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamineâ€“Rich Tetratricopeptide Repeat Containing Protein Î±. Cancer Research, 2007, 67, 10087-10096.	0.4	82
67	Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate, 2007, 67, 288-300.	1.2	11
68	Extracellular Matrix of Ovarian Tumors. Seminars in Reproductive Medicine, 2006, 24, 270-282.	0.5	105
69	Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant. Molecular Endocrinology, 2006, 20, 1009-1024.	3.7	17
70	Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate, 2005, 63, 19-28.	1.2	103
71	Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate. Cancer Research, 2005, 65, 8487-8496.	0.4	58
72	Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer. Clinical Cancer Research, 2004, 10, 2491-2498.	3.2	129

#	Article	IF	Citations
73	Androgen Receptor Signaling. Cancer Research, 2004, 64, 2619-2626.	0.4	74
74	Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. Prostate, 2004, 58, 103-108.	1.2	32
75	Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues. Anticancer Research, 2003, 23, 1479-88.	0.5	18
76	Modulation of prostate cancer cell attachment to matrix by versican. Cancer Research, 2003, 63, 4786-91.	0.4	65
77	A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Research, 2002, 62, 854-9.	0.4	131
78	Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clinical Cancer Research, 2002, 8, 1054-60.	3.2	120
79	A simple index using video image analysis to predict disease outcome in primary breast cancer. , 1999, 84, 203-208.		25
80	IMMUNOLOCALIZATION OF APOLIPOPROTEIN D, ANDROGEN RECEPTOR AND PROSTATE SPECIFIC ANTIGEN IN EARLY STAGE PROSTATE CANCERS. Journal of Urology, 1998, 159, 548-554.	0.2	23
81	Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 459-467.	1.2	226
82	Effects of oestradiol-17Î² and 5Î±-dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. Journal of Endocrinology, 1994, 140, 373-383.	1.2	17
83	Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. In Vitro Cellular & Developmental Biology, 1989, 25, 1016-1024.	1.0	29
84	STEROID HORMONE AND EPIDERMAL GROWTH FACTOR RECEPTORS IN MENINGIOMAS. ANZ Journal of Surgery, 1989, 59, 881-888.	0.3	18
85	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 0, , 5.	0.2	2